Hydroxychloroquine Pill
Phase 2Small molecule
Hydroxychloroquine Pill is one of 78 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
3
Indications
5
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Biaxin
AbbViePreclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Phase 2
Singulair
AstraZenecaPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Orap
TevaPreclinical
Aprotinin
BayerPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-192 trials
Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
Unknown status·—·Phase 2/3·NCT04443725·100 enrolled
COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience
Completed·—··NCT04554979·199 enrolled
Metastatic Colorectal Cancer1 trial
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Terminated·—·Phase 1·NCT04873895·5 enrolled
Non-Small Cell Lung Cancer1 trial
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT04735068·9 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydroxychloroquine Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Calgary